This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia—a phase 3 study
Leukemia Open Access 01 October 2018
-
Priority-Lasso: a simple hierarchical approach to the prediction of clinical outcome using multi-omics data
BMC Bioinformatics Open Access 12 September 2018
-
Mediation analysis reveals common mechanisms of RUNX1 point mutations and RUNX1/RUNX1T1 fusions influencing survival of patients with acute myeloid leukemia
Scientific Reports Open Access 26 July 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Buchner T, Berdel WE, Haferlach C, Haferlach T, Schnittger S, Muller-Tidow C et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 2009; 27: 61–69.
Gale RP, Cline MJ . High remission-induction rate in acute myeloid leukaemia. Lancet 1977; 1: 497–499.
Stelljes M, Krug U, Beelen DW, Braess J, Sauerland MC, Heineke A et al. Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis. J Clin Oncol 2014; 32: 288–296.
Buchner T, Berdel WE, Hiddemann W . Priming with granulocyte colony-stimulating factor—relation to high-dose cytarabine in acute myeloid leukemia. N Engl J Med 2004; 350: 2215–2216.
Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453–474.
Falini B, Macijewski K, Weiss T, Bacher U, Schnittger S, Kern W et al. Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1). Blood 2010; 115: 3776–3786.
Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996; 10: 1911–1918.
Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, Schnittger S et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet 2010; 27: 263–270.
Rosthoj S, Andersen PK, Abildstrom SZ . SAS macros for estimation of the cumulative incidence functions based on a Cox regression model for competing risks survival data. Comput Methods Prog Biomed 2004; 74: 69–75.
Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21: 4642–4649.
Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer Leukemia Group B. N Engl J Med 1994; 331: 896–903.
Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE et al. Age and acute myeloid leukemia. Blood 2006; 107: 3481–3485.
Wheatley K, Brookes CL, Howman AJ, Goldstone AH, Milligan DW, Pentice AG et al. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol 2009; 145: 598–605.
Mrozek K, Marcucci G, Nicolet D, Maharry KS, Becker H, Whitman S et al. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol 2012; 30: 4515–4523.
Buchner T, Berdel WE, Woermann BJ, Sauerland MC, Heinecke A, Krug U et al. Upfront randomization 10 years later: The AML Cooperative Group Strategy. Blood 2014; 124: 2267.
Acknowledgements
Ms Birgit Mayerhoffer and Sabine Jacob helped to prepare the typescript. RPG acknowledges support from the National Institute of Health Research (NIHR) Biomedical Research Centre funding scheme.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Büchner, T., Krug, U., Peter Gale, R. et al. Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia. Leukemia 30, 1781–1784 (2016). https://doi.org/10.1038/leu.2016.54
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2016.54
This article is cited by
-
Priority-Lasso: a simple hierarchical approach to the prediction of clinical outcome using multi-omics data
BMC Bioinformatics (2018)
-
Mediation analysis reveals common mechanisms of RUNX1 point mutations and RUNX1/RUNX1T1 fusions influencing survival of patients with acute myeloid leukemia
Scientific Reports (2018)
-
Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia—a phase 3 study
Leukemia (2018)
-
How good are we at predicting the fate of someone with acute myeloid leukaemia?
Leukemia (2017)
-
Commentary on: ‘Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia’
Leukemia (2016)